Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Leukocyte-rich platelet-rich plasma (LR-PRP) is an autologous blood-derived biologic therapy characterized by a high concentration of platelets and leukocytes compared to baseline whole blood. In the clinical context of the Clinical Center of Vojvodina, it is prepared using a double-spinning process (e.g., via the Arthrex Angel Centrifuge) to concentrate growth factors and immune cells from a patient's own blood. The therapeutic rationale for its use in knee osteoarthritis lies in the release of bioactive proteins from platelet alpha-granules, such as PDGF, TGF-β, and VEGF, which promote tissue repair, modulate the intra-articular inflammatory environment, and stimulate chondrocyte proliferation. The inclusion of leukocytes is intended to provide additional signaling molecules and potentially enhance the regenerative response, although their specific role in joint inflammation remains a subject of clinical investigation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on leukocyte-rich platelet-rich plasma (Clinical Center of Vojvodina).